Arterra Bioscience SpA (MIL:ARBS) Current Deferred Revenue: € Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:ARBS Arterra Bioscience SpA MIL:ARBS
80 GF Score
Price €3.10
GF Value €2.94
Valuation Fairly Valued
View Full Analysis

What is Arterra Bioscience SpA Current Deferred Revenue?

Arterra Bioscience SpA MIL:ARBS 80 Current Deferred Revenue is € Mil as of Dec. 2025. GuruFocus rates MIL:ARBS with a GF Score™ of 80/100 and a GF Value™ of €2.94 (Fairly Valued).

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Arterra Bioscience SpA's current deferred revenue for the quarter that ended in Dec. 2025 was € Mil.

Arterra Bioscience SpA Current Deferred Revenue Related Terms

Arterra Bioscience SpA Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Arterra Bioscience SpA's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arterra Bioscience SpA Current Deferred Revenue Chart

Arterra Bioscience SpA Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only - - - - -

Arterra Bioscience SpA Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
MIL:ARBS
80GF Score
Arterra Bioscience SpA MIL:ARBS
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of € Mil mean?
Arterra Bioscience SpA (MIL:ARBS) has a Current Deferred Revenue of € Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Arterra Bioscience SpA and its competitors.
Is Arterra Bioscience SpA's Current Deferred Revenue too high?
Arterra Bioscience SpA's current Current Deferred Revenue is € Mil. Overall, Arterra Bioscience SpA has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Current Deferred Revenue compare to VRTX and REGN?
Arterra Bioscience SpA's Current Deferred Revenue of € Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Arterra Bioscience SpA and its competitors. Arterra Bioscience SpA's current Current Deferred Revenue is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.94, compared to a current price of €3.10 — trading 5.4% above its estimated fair value. The current Current Deferred Revenue is € Mil. Arterra Bioscience SpA's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Current Deferred Revenue is € Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?

Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued. The current stock price of €3.10 is trading 5.4% above its estimated GF Value™ of €2.94. GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.

Key valuation signals for MIL:ARBS:

  • Current Deferred Revenue: € Mil
  • GF Value™: €2.94 vs. price of €3.10 (5.4% above fair value)
  • GF Score™: 80/100

No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arterra Bioscience SpA Business Description

Address via Benedetto Brin, 69, Napoli, ITA, 80142
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
80GF Score

Get the complete analysis for MIL:ARBS

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10
Price
€2.94
GF Value